
    
      This is a double-blind, placebo-controlled, randomized, multiple-dose, parallel group,
      multicenter study. Up to 20 male and female subjects with mild to moderate Alzheimer's
      disease (AD) who are taking stable doses of acetylcholinesterase inhibitors will be enrolled
      in this study. The study will be conducted in up to four sites. Within 28 days prior to study
      drug administration, subjects will be screened based on National Institute of Neurological
      and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association
      (NINCDS/ADRDA) criteria for probable AD, Mini-Mental State Examination (MMSE) and Modified
      Hachinski Ischemic Scale (MHIS) scores, medical history, physical examination, neurological
      examination, vital signs, ECG, laboratory tests and response to Columbia-Suicide Severity
      Rating Scale (C-SSRS).

      Subjects will be divided into two groups of 10 subjects each. In each group, 8 subjects will
      receive ABT-126 and two subjects will receive matching placebo. Group 1 will be administered
      Dose 1 of ABT-126 or placebo. Group 2 will be administered Dose 2 ABT-126 or placebo. All
      doses will be administered once daily in the morning for 10 days.
    
  